Radiology of fibrosis. Part I: Thoracic organs.
Fibrosis
Imaging
Thoracic organs
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
02 Jul 2024
02 Jul 2024
Historique:
received:
12
02
2024
accepted:
27
04
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
3
7
2024
Statut:
epublish
Résumé
Sustained injury from factors such as hypoxia, infection, or physical damage may provoke improper tissue repair and the anomalous deposition of connective tissue that causes fibrosis. This phenomenon may take place in any organ, ultimately leading to their dysfunction and eventual failure. Tissue fibrosis has also been found to be central in both the process of carcinogenesis and cancer progression. Thus, its prompt diagnosis and regular monitoring is necessary for implementing effective disease-modifying interventions aiming to reduce mortality and improve overall quality of life. While significant research has been conducted on these subjects, a comprehensive understanding of how their relationship manifests through modern imaging techniques remains to be established. This work intends to provide a comprehensive overview of imaging technologies relevant to the detection of fibrosis affecting thoracic organs as well as to explore potential future advancements in this field.
Identifiants
pubmed: 38956586
doi: 10.1186/s12967-024-05244-1
pii: 10.1186/s12967-024-05244-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
609Informations de copyright
© 2024. The Author(s).
Références
Chandler C, Liu T, Buckanovich R, Coffman LG. The double edge sword of fibrosis in cancer. Transl Res. 2019;209:55–67. https://doi.org/10.1016/j.trsl.2019.02.006 .
doi: 10.1016/j.trsl.2019.02.006
pubmed: 30871956
pmcid: 6545239
Roman J, Barnes TR, Kervitsky DJ, et al. The fibrosis across organs symposium: a roadmap for future research priorities. Am J Med Sci. 2019;357(5):405–10. https://doi.org/10.1016/j.amjms.2019.02.014 .
doi: 10.1016/j.amjms.2019.02.014
pubmed: 31010467
pmcid: 7219529
Kumar V, Abbas AK, Aster JC. Robbins and cotran: pathologic basis of disease. 8th ed. Saunders: Elsevier; 2005.
Henderson NCRF, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020;587(7835):555–66. https://doi.org/10.1038/s41586-020-2938-9 .
doi: 10.1038/s41586-020-2938-9
pubmed: 33239795
pmcid: 8034822
CGMLDR SG. In: Fitridge R, Thompson M, eds. Mechanisms of vascular disease: a reference book for vascular specialists. University of Adelaide Press
Reinke JM, Sorg H. Wound repair and regeneration. Eur Surg Res. 2012;49(1):35–43. https://doi.org/10.1159/000339613 .
doi: 10.1159/000339613
pubmed: 22797712
Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol Life Sci. 2016;73(20):3861–85. https://doi.org/10.1007/s00018-016-2268-0 .
doi: 10.1007/s00018-016-2268-0
pubmed: 27180275
pmcid: 5021733
Bitto N, Liguori E, La Mura V. Coagulation, microenvironment and liver fibrosis. Cells. 2018;7(8):85. https://doi.org/10.3390/cells7080085 .
doi: 10.3390/cells7080085
pubmed: 30042349
pmcid: 6115868
Fiorucci S, Antonelli E, Distrutti E, et al. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology. 2004;39(2):365–75. https://doi.org/10.1002/hep.20054 .
doi: 10.1002/hep.20054
pubmed: 14767989
Pant A, Kopec AK, Luyendyk JP. Role of the blood coagulation cascade in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol. 2018;315(2):G171-g176. https://doi.org/10.1152/ajpgi.00402.2017 .
doi: 10.1152/ajpgi.00402.2017
pubmed: 29723040
pmcid: 6139645
Gonzalez AC, Costa TF, Andrade ZA, Medrado AR. Wound healing—a literature review. An Bras Dermatol. 2016;91(5):614–20. https://doi.org/10.1590/abd1806-4841.20164741 .
doi: 10.1590/abd1806-4841.20164741
pubmed: 27828635
pmcid: 5087220
Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118. https://doi.org/10.1146/annurev-pathol-121808-102144 .
doi: 10.1146/annurev-pathol-121808-102144
pubmed: 20078217
pmcid: 4166495
Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, Horowitz JC. Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol. 2009;41(4):484–93. https://doi.org/10.1165/rcmb.2008-0447OC .
doi: 10.1165/rcmb.2008-0447OC
pubmed: 19188658
pmcid: 2746991
Hinz B, Gabbiani G. Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives. Biol Rep. 2010;2:78. https://doi.org/10.3410/b2-78 .
doi: 10.3410/b2-78
Santen RJ. Benign breast disease in women. In: Feingold KR, Anawalt B, Blackman MR, et al, editors. Endotext. MDText.com, Inc. Copyright
Vinnicombe SJ. Breast density: why all the fuss? Clin Radiol. 2018;73(4):334–57. https://doi.org/10.1016/j.crad.2017.11.018 .
doi: 10.1016/j.crad.2017.11.018
pubmed: 29273225
Stachs A, Stubert J, Reimer T, Hartmann S. Benign breast disease in women. Dtsch Arztebl Int. 2019;116(33–34):565–74. https://doi.org/10.3238/arztebl.2019.0565 .
doi: 10.3238/arztebl.2019.0565
pubmed: 31554551
pmcid: 6794703
Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. Am J Obstet Gynecol. 1986;154(1):161–79. https://doi.org/10.1016/0002-9378(86)90421-7 .
doi: 10.1016/0002-9378(86)90421-7
pubmed: 3511705
Sklair-Levy M, Samuels TH, Catzavelos C, Hamilton P, Shumak R. Stromal fibrosis of the breast. AJR Am J Roentgenol. 2001;177(3):573–7. https://doi.org/10.2214/ajr.177.3.1770573 .
doi: 10.2214/ajr.177.3.1770573
pubmed: 11517049
Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003;5(5):R129–35. https://doi.org/10.1186/bcr622 .
doi: 10.1186/bcr622
pubmed: 12927043
pmcid: 314426
Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2007;99(15):1178–87. https://doi.org/10.1093/jnci/djm062 .
doi: 10.1093/jnci/djm062
pubmed: 17652278
Brisson J, Brisson B, Coté G, Maunsell E, Bérubé S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev. 2000;9(9):911–5.
pubmed: 11008908
Pankow JS, Vachon CM, Kuni CC, et al. Genetic analysis of mammographic breast density in adult women: evidence of a gene effect. J Natl Cancer Inst. 1997;89(8):549–56. https://doi.org/10.1093/jnci/89.8.549 .
doi: 10.1093/jnci/89.8.549
pubmed: 9106643
Vachon CM, King RA, Atwood LD, Kuni CC, Sellers TA. Preliminary sibpair linkage analysis of percent mammographic density. J Natl Cancer Inst. 1999;91(20):1778–9. https://doi.org/10.1093/jnci/91.20.1778 .
doi: 10.1093/jnci/91.20.1778
pubmed: 10528030
Haiman CA, Bernstein L, Berg D, Ingles SA, Salane M, Ursin G. Genetic determinants of mammographic density. Breast Cancer Res. 2002;4(3):R5. https://doi.org/10.1186/bcr434 .
doi: 10.1186/bcr434
pubmed: 12052257
pmcid: 111030
Haiman CA, Hankinson SE, De Vivo I, et al. Polymorphisms in steroid hormone pathway genes and mammographic density. Breast Cancer Res Treat. 2003;77(1):27–36. https://doi.org/10.1023/a:1021112121782 .
doi: 10.1023/a:1021112121782
pubmed: 12602902
Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med. 2002;347(12):886–94. https://doi.org/10.1056/NEJMoa013390 .
doi: 10.1056/NEJMoa013390
pubmed: 12239257
Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res. 2000;60(14):3744–8.
pubmed: 10919644
Malik N, Lad S, Seely JM, Schweitzer ME. Underestimation of malignancy in biopsy-proven cases of stromal fibrosis. Br J Radiol. 2014;87(1039):20140182. https://doi.org/10.1259/bjr.20140182 .
doi: 10.1259/bjr.20140182
pubmed: 24846442
pmcid: 4075591
Dhamija E, Gulati M, Deo SVS, Gogia A, Hari S. Digital breast tomosynthesis: an overview. Indian J Surg Oncol. 2021;12(2):315–29. https://doi.org/10.1007/s13193-021-01310-y .
doi: 10.1007/s13193-021-01310-y
pubmed: 34295076
pmcid: 8272763
Margolies LR, Salvatore M, Yip R, et al. The chest radiologist’s role in invasive breast cancer detection. Clin Imaging. 2018;50:13–9. https://doi.org/10.1016/j.clinimag.2017.12.002 .
doi: 10.1016/j.clinimag.2017.12.002
pubmed: 29245142
Margolies L, Salvatore M, Eber C, et al. The general radiologist’s role in breast cancer risk assessment: breast density measurement on chest CT. Clin Imaging. 2015;39(6):979–82. https://doi.org/10.1016/j.clinimag.2015.05.010 .
doi: 10.1016/j.clinimag.2015.05.010
pubmed: 26210389
Weigert J, Steenbergen S. The connecticut experiment: the role of ultrasound in the screening of women with dense breasts. Breast J. 2012;18(6):517–22. https://doi.org/10.1111/tbj.12003 .
doi: 10.1111/tbj.12003
pubmed: 23009208
Hooley RJ, Greenberg KL, Stackhouse RM, Geisel JL, Butler RS, Philpotts LE. Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09–41. Radiology. 2012;265(1):59–69. https://doi.org/10.1148/radiol.12120621 .
doi: 10.1148/radiol.12120621
pubmed: 22723501
Chetlen A, Mack J, Chan T. Breast cancer screening controversies: who, when, why, and how? Clin Imaging. 2016;40(2):279–82. https://doi.org/10.1016/j.clinimag.2015.05.017 .
doi: 10.1016/j.clinimag.2015.05.017
pubmed: 26093511
Chong A, Weinstein SP, McDonald ES, Conant EF. Digital breast tomosynthesis: concepts and clinical practice. Radiology. 2019;292(1):1–14. https://doi.org/10.1148/radiol.2019180760 .
doi: 10.1148/radiol.2019180760
pubmed: 31084476
Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394–404. https://doi.org/10.1001/jama.2012.388 .
doi: 10.1001/jama.2012.388
pubmed: 22474203
pmcid: 3891886
Prionas ND, Lindfors KK, Ray S, et al. Contrast-enhanced dedicated breast CT: initial clinical experience. Radiology. 2010;256(3):714–23. https://doi.org/10.1148/radiol.10092311 .
doi: 10.1148/radiol.10092311
pubmed: 20720067
pmcid: 2923727
Zhu Y, O’Connell AM, Ma Y, et al. Dedicated breast CT: state of the art-Part II. Clinical application and future outlook. Eur Radiol. 2022;32(4):2286–300. https://doi.org/10.1007/s00330-021-08178-0 .
doi: 10.1007/s00330-021-08178-0
pubmed: 34476564
Formaz E, Schmidt C, Berger N, et al. Dedicated breast computed-tomography in women with a personal history of breast cancer: a proof-of-concept study. Eur J Radiol. 2023;158: 110632. https://doi.org/10.1016/j.ejrad.2022.110632 .
doi: 10.1016/j.ejrad.2022.110632
pubmed: 36463702
Glick SJ, Breast CT. Annu Rev Biomed Eng. 2007;9:501–26. https://doi.org/10.1146/annurev.bioeng.9.060906.151924 .
doi: 10.1146/annurev.bioeng.9.060906.151924
pubmed: 17506654
O’Connell AM, Karellas A, Vedantham S, Kawakyu-O’Connor DT. Newer technologies in breast cancer imaging: dedicated cone-beam breast computed tomography. Semin Ultrasound CT MR. 2018;39(1):106–13. https://doi.org/10.1053/j.sult.2017.09.001 .
doi: 10.1053/j.sult.2017.09.001
pubmed: 29317032
Aminololama-Shakeri S, Abbey CK, López JE, et al. Conspicuity of suspicious breast lesions on contrast enhanced breast CT compared to digital breast tomosynthesis and mammography. Br J Radiol. 2019;92(1097):20181034. https://doi.org/10.1259/bjr.20181034 .
doi: 10.1259/bjr.20181034
pubmed: 30810339
pmcid: 6580915
Desperito E, Schwartz L, Capaccione KM, et al. Chest CT for breast cancer diagnosis. Life (Basel). 2022;12(11):1699. https://doi.org/10.3390/life12111699 .
doi: 10.3390/life12111699
pubmed: 36362854
pmcid: 9695285
Georgieva M, Rennert J, Brochhausen C, Stroszczynski C, Jung EM. Suspicious breast lesions incidentally detected on chest computer tomography with histopathological correlation. Breast J. 2021;27(9):715–22. https://doi.org/10.1111/tbj.14259 .
doi: 10.1111/tbj.14259
pubmed: 34124813
Mann RM, Balleyguier C, Baltzer PA, et al. Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol. 2015;25(12):3669–78. https://doi.org/10.1007/s00330-015-3807-z .
doi: 10.1007/s00330-015-3807-z
pubmed: 26002130
pmcid: 4636525
Pineda FD, Medved M, Fan X, Karczmar GS. B1 and T1 mapping of the breast with a reference tissue method. Magn Reson Med. 2016;75(4):1565–73. https://doi.org/10.1002/mrm.25751 .
doi: 10.1002/mrm.25751
pubmed: 26014575
Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet. 2011;378(9805):1804–11. https://doi.org/10.1016/s0140-6736(11)61350-0 .
doi: 10.1016/s0140-6736(11)61350-0
pubmed: 22098853
Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296–316. https://doi.org/10.1016/j.ejca.2010.02.015 .
doi: 10.1016/j.ejca.2010.02.015
pubmed: 20304629
Bignotti B, Succio G, Nosenzo F, et al. Breast findings incidentally detected on body MRI. Springerplus. 2016;5(1):781. https://doi.org/10.1186/s40064-016-2343-x .
doi: 10.1186/s40064-016-2343-x
pubmed: 27386267
pmcid: 4912526
Salvatore M, Margolies L, Kale M, et al. Breast density: comparison of chest CT with mammography. Radiology. 2014;270(1):67–73. https://doi.org/10.1148/radiol.13130733 .
doi: 10.1148/radiol.13130733
pubmed: 24126363
Yi JG, Kim SJ, Marom EM, Park JH, Jung SI, Lee MW. Chest CT of incidental breast lesions. J Thorac Imaging. 2008;23(2):148–55. https://doi.org/10.1097/RTI.0b013e318156eb52 .
doi: 10.1097/RTI.0b013e318156eb52
pubmed: 18520577
Poyraz N, Emlik GD, Keskin S, Kalkan H. Incidental breast lesions detected on computed thorax tomography. J Breast Health. 2015;11(4):163–7. https://doi.org/10.5152/tjbh.2015.2656 .
doi: 10.5152/tjbh.2015.2656
pubmed: 28331715
pmcid: 5351420
Falomo E, Strigel RM, Bruce R, Munoz Del Rio A, Adejumo C, Kelcz F. Incidence and outcomes of incidental breast lesions detected on cross-sectional imaging examinations. Breast J. 2018;24(5):743–8. https://doi.org/10.1111/tbj.13040 .
doi: 10.1111/tbj.13040
pubmed: 29687537
Margolies LR, Salvatore M, Tam K, et al. Breast mass assessment on chest CT: axial, sagittal, coronal or maximal intensity projection? Clin Imaging. 2020;63:60–4. https://doi.org/10.1016/j.clinimag.2020.02.011 .
doi: 10.1016/j.clinimag.2020.02.011
pubmed: 32146335
Salvatore M, Margolies L, Bertolini A, Singh A, Yankelevitz D, Henschke C. The need to be all inclusive: chest CT scans should include imaged breast parenchyma. Clin Imaging. 2018;50:243–5. https://doi.org/10.1016/j.clinimag.2018.04.006 .
doi: 10.1016/j.clinimag.2018.04.006
pubmed: 29689480
Ranzenberger LR, Booth KA. Mammoscintigraphy. StatPearls. StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC.; 2023.
King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–61. https://doi.org/10.1016/s0140-6736(11)60052-4 .
doi: 10.1016/s0140-6736(11)60052-4
pubmed: 21719092
Smith M, Dalurzo M, Panse P, Parish J, Leslie K. Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology. J Clin Pathol. 2013;66(10):896–903. https://doi.org/10.1136/jclinpath-2013-201442 .
doi: 10.1136/jclinpath-2013-201442
pubmed: 23703852
Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J. 2004;11(2):117–22. https://doi.org/10.1155/2004/379723 .
doi: 10.1155/2004/379723
pubmed: 15045042
Alhamad EH, Cal JG, Alrajhi NN, AlBoukai AA. Acute exacerbation in interstitial lung disease. Ann Thorac Med. 2021;16(2):178–87. https://doi.org/10.4103/atm.atm_14_21 .
doi: 10.4103/atm.atm_14_21
pubmed: 34012485
pmcid: 8109689
Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143–50. https://doi.org/10.1183/09031936.06.00114004 .
doi: 10.1183/09031936.06.00114004
pubmed: 16387947
Farrand E, Vittinghoff E, Ley B, Butte AJ, Collard HR. Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. Respirology. 2020;25(6):629–35. https://doi.org/10.1111/resp.13753 .
doi: 10.1111/resp.13753
pubmed: 31846126
Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265–75. https://doi.org/10.1164/rccm.201604-0801CI .
doi: 10.1164/rccm.201604-0801CI
pubmed: 27299520
Glaspole IN. Acute exacerbations in IPF: a clarion call for collaborative research. Respirology. 2020;25(6):572–3. https://doi.org/10.1111/resp.13770 .
doi: 10.1111/resp.13770
pubmed: 31997468
Leuschner G, Behr J. Acute exacerbation in interstitial lung disease. Front Med (Lausanne). 2017;4:176. https://doi.org/10.3389/fmed.2017.00176 .
doi: 10.3389/fmed.2017.00176
pubmed: 29109947
Car BD, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med. 1994;149(3 Pt 1):655–9. https://doi.org/10.1164/ajrccm.149.3.8118632 .
doi: 10.1164/ajrccm.149.3.8118632
pubmed: 8118632
Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345(7):517–25. https://doi.org/10.1056/NEJMra003200 .
doi: 10.1056/NEJMra003200
pubmed: 11519507
Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77. https://doi.org/10.1056/NEJMoa1113354 .
doi: 10.1056/NEJMoa1113354
pubmed: 22607134
Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal. 2008;10(2):287–301. https://doi.org/10.1089/ars.2007.1897 .
doi: 10.1089/ars.2007.1897
pubmed: 17961066
Ogushi F, Tani K, Maniwa K, et al. Interleukin-8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis or idiopathic pulmonary fibrosis. J Med Invest. 1997;44(1–2):53–8.
pubmed: 9395718
Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722. https://doi.org/10.1148/radiol.2462070712 .
doi: 10.1148/radiol.2462070712
pubmed: 18195376
Arakawa H, Honma K. Honeycomb lung: history and current concepts. AJR Am J Roentgenol. 2011;196(4):773–82. https://doi.org/10.2214/ajr.10.4873 .
doi: 10.2214/ajr.10.4873
pubmed: 21427324
Kishaba T. Acute exacerbation of idiopathic pulmonary fibrosis. Medicina (Kaunas). 2019;55(3):70. https://doi.org/10.3390/medicina55030070 .
doi: 10.3390/medicina55030070
pubmed: 30884853
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–68. https://doi.org/10.1164/rccm.201807-1255ST .
doi: 10.1164/rccm.201807-1255ST
pubmed: 30168753
Nardocci C, Simon J, Kiss F, et al. The role of imaging in the diagnosis and management of idiopathic pulmonary fibrosis. Imaging. 2022;14(1):16–27. https://doi.org/10.1556/1647.2021.00048 .
doi: 10.1556/1647.2021.00048
Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6(2):138–53. https://doi.org/10.1016/s2213-2600(17)30433-2 .
doi: 10.1016/s2213-2600(17)30433-2
pubmed: 29154106
Cozzi D, Cavigli E, Moroni C, et al. Ground-glass opacity (GGO): a review of the differential diagnosis in the era of COVID-19. Jpn J Radiol. 2021;39(8):721–32. https://doi.org/10.1007/s11604-021-01120-w .
doi: 10.1007/s11604-021-01120-w
pubmed: 33900542
pmcid: 8071755
Mammarappallil JG, Rankine L, Wild JM, Driehuys B. New developments in imaging idiopathic pulmonary fibrosis with hyperpolarized xenon magnetic resonance imaging. J Thorac Imaging. 2019;34(2):136–50. https://doi.org/10.1097/rti.0000000000000392 .
doi: 10.1097/rti.0000000000000392
pubmed: 30801449
pmcid: 6392051
Maldonado F, Moua T, Rajagopalan S, et al. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J. 2014;43(1):204–12. https://doi.org/10.1183/09031936.00071812 .
doi: 10.1183/09031936.00071812
pubmed: 23563264
Jacob J, Bartholmai BJ, Rajagopalan S, et al. Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis. Am J Respir Crit Care Med. 2018;198(6):767–76. https://doi.org/10.1164/rccm.201711-2174OC .
doi: 10.1164/rccm.201711-2174OC
pubmed: 29684284
pmcid: 6222463
Takahashi M, Togao O, Obara M, et al. Ultra-short echo time (UTE) MR imaging of the lung: comparison between normal and emphysematous lungs in mutant mice. J Magn Reson Imaging. 2010;32(2):326–33. https://doi.org/10.1002/jmri.22267 .
doi: 10.1002/jmri.22267
pubmed: 20677258
pmcid: 2915456
Bankier AA, Storey P, Mai VM, Edelman RR, Chen Q. Gravity-dependent signal gradients on MR images of the lung in supine and prone positions: a comparison with isogravitational signal variability. J Magn Reson Imaging. 2006;23(2):115–22. https://doi.org/10.1002/jmri.20478 .
doi: 10.1002/jmri.20478
pubmed: 16400636
Quintana HK, Cannet C, Zurbruegg S, et al. Proton MRI as a noninvasive tool to assess elastase-induced lung damage in spontaneously breathing rats. Magn Reson Med. 2006;56(6):1242–50. https://doi.org/10.1002/mrm.21051 .
doi: 10.1002/mrm.21051
pubmed: 17029230
Failo R, Wielopolski PA, Tiddens HA, Hop WC, Mucelli RP, Lequin MH. Lung morphology assessment using MRI: a robust ultra-short TR/TE 2D steady state free precession sequence used in cystic fibrosis patients. Magn Reson Med. 2009;61(2):299–306. https://doi.org/10.1002/mrm.21841 .
doi: 10.1002/mrm.21841
pubmed: 19165879
Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362–70. https://doi.org/10.1513/AnnalsATS.201303-069FR .
doi: 10.1513/AnnalsATS.201303-069FR
pubmed: 23952859
Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):123–9.
pubmed: 22117503
Suliman S, Al Harash A, Roberts WN, Perez RL, Roman J. Scleroderma-related interstitial lung disease. Respir Med Case Rep. 2017;22:109–12. https://doi.org/10.1016/j.rmcr.2017.07.007 .
doi: 10.1016/j.rmcr.2017.07.007
pubmed: 28761806
pmcid: 5524221
Peelen DM, Zwezerijnen B, Nossent EJ, et al. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology (Oxford). 2020;59(6):1407–15. https://doi.org/10.1093/rheumatology/kez483 .
doi: 10.1093/rheumatology/kez483
pubmed: 31642912
Bae K, Jeon KN, Hwang MJ, et al. Comparison of lung imaging using three-dimensional ultrashort echo time and zero echo time sequences: preliminary study. Eur Radiol. 2019;29(5):2253–62. https://doi.org/10.1007/s00330-018-5889-x .
doi: 10.1007/s00330-018-5889-x
pubmed: 30547204
Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020;9(5):1417. https://doi.org/10.3390/jcm9051417 .
doi: 10.3390/jcm9051417
pubmed: 32403217
pmcid: 7290769
Scialo F, Daniele A, Amato F, et al. ACE2: the major cell entry receptor for SARS-CoV-2. Lung. 2020;198(6):867–77. https://doi.org/10.1007/s00408-020-00408-4 .
doi: 10.1007/s00408-020-00408-4
pubmed: 33170317
pmcid: 7653219
Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8. https://doi.org/10.1016/s0140-6736(20)30937-5 .
doi: 10.1016/s0140-6736(20)30937-5
pubmed: 32325026
pmcid: 7172722
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–7. https://doi.org/10.1016/s2213-2600(20)30216-2 .
doi: 10.1016/s2213-2600(20)30216-2
pubmed: 32353251
Lang M, Som A, Mendoza DP, et al. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. Lancet Infect Dis. 2020;20(12):1365–6. https://doi.org/10.1016/s1473-3099(20)30367-4 .
doi: 10.1016/s1473-3099(20)30367-4
pubmed: 32359410
pmcid: 7252023
Barry K. Chronic pancreatitis: diagnosis and treatment. Am Fam Physician. 2018;97(6):385–93.
pubmed: 29671537
Endeman H, van der Zee P, van Genderen ME, van den Akker JPC, Gommers D. Progressive respiratory failure in COVID-19: a hypothesis. Lancet Infect Dis. 2020;20(12):1365. https://doi.org/10.1016/s1473-3099(20)30366-2 .
doi: 10.1016/s1473-3099(20)30366-2
pubmed: 32530428
pmcid: 7190290
Machida H, Tanaka I, Fukui R, et al. Dual-energy spectral CT: various clinical vascular applications. Radiographics. 2016;36(4):1215–32. https://doi.org/10.1148/rg.2016150185 .
doi: 10.1148/rg.2016150185
pubmed: 27399244
Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. https://doi.org/10.1183/13993003.00607-2020 .
doi: 10.1183/13993003.00607-2020
pubmed: 32269085
Franks TJ, Chong PY, Chui P, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol. 2003;34(8):743–8. https://doi.org/10.1016/s0046-8177(03)00367-8 .
doi: 10.1016/s0046-8177(03)00367-8
pubmed: 14506633
pmcid: 7119137
Tian J, An X, Niu L. Myocardial fibrosis in congenital and pediatric heart disease. Exp Ther Med. 2017;13(5):1660–4. https://doi.org/10.3892/etm.2017.4224 .
doi: 10.3892/etm.2017.4224
pubmed: 28565750
pmcid: 5443200
Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71(4):549–74. https://doi.org/10.1007/s00018-013-1349-6 .
doi: 10.1007/s00018-013-1349-6
pubmed: 23649149
Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450–88. https://doi.org/10.1093/cvr/cvaa324 .
doi: 10.1093/cvr/cvaa324
pubmed: 33135058
Qin W, Cao L, Massey IY. Role of PI3K/Akt signaling pathway in cardiac fibrosis. Mol Cell Biochem. 2021;476(11):4045–59. https://doi.org/10.1007/s11010-021-04219-w .
doi: 10.1007/s11010-021-04219-w
pubmed: 34244974
Ma ZG, Yuan YP, Wu HM, Zhang X, Tang QZ. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci. 2018;14(12):1645–57. https://doi.org/10.7150/ijbs.28103 .
doi: 10.7150/ijbs.28103
pubmed: 30416379
pmcid: 6216032
Jiang W, Xiong Y, Li X, Yang Y. Cardiac fibrosis: cellular effectors, molecular pathways, and exosomal roles. Front Cardiovasc Med. 2021;8: 715258. https://doi.org/10.3389/fcvm.2021.715258 .
doi: 10.3389/fcvm.2021.715258
pubmed: 34485413
pmcid: 8415273
Park S, Nguyen NB, Pezhouman A, Ardehali R. Cardiac fibrosis: potential therapeutic targets. Transl Res. 2019;209:121–37. https://doi.org/10.1016/j.trsl.2019.03.001 .
doi: 10.1016/j.trsl.2019.03.001
pubmed: 30930180
pmcid: 6545256
Jellis C, Martin J, Narula J, Marwick TH. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol. 2010;56(2):89–97. https://doi.org/10.1016/j.jacc.2010.02.047 .
doi: 10.1016/j.jacc.2010.02.047
pubmed: 20620723
Mandoli GE, D’Ascenzi F, Vinco G, et al. Novel approaches in cardiac imaging for non-invasive assessment of left heart myocardial fibrosis. Front Cardiovasc Med. 2021;8: 614235. https://doi.org/10.3389/fcvm.2021.614235 .
doi: 10.3389/fcvm.2021.614235
pubmed: 33937354
pmcid: 8081830
Weidemann F, Niemann M, Herrmann S, et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J. 2007;28(24):3020–6. https://doi.org/10.1093/eurheartj/ehm454 .
doi: 10.1093/eurheartj/ehm454
pubmed: 17981828
Mondillo S, Galderisi M, Mele D, et al. Speckle-tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med. 2011;30(1):71–83. https://doi.org/10.7863/jum.2011.30.1.71 .
doi: 10.7863/jum.2011.30.1.71
pubmed: 21193707
Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891–903. https://doi.org/10.1016/j.jacc.2010.11.013 .
doi: 10.1016/j.jacc.2010.11.013
pubmed: 21329834
Salerno M, Kramer CM. Advances in parametric mapping with CMR imaging. JACC Cardiovasc Imaging. 2013;6(7):806–22. https://doi.org/10.1016/j.jcmg.2013.05.005 .
doi: 10.1016/j.jcmg.2013.05.005
pubmed: 23845576
pmcid: 4073213
Burt JR, Zimmerman SL, Kamel IR, Halushka M, Bluemke DA. Myocardial T1 mapping: techniques and potential applications. Radiographics. 2014;34(2):377–95. https://doi.org/10.1148/rg.342125121 .
doi: 10.1148/rg.342125121
pubmed: 24617686
Jellis CL, Kwon DH. Myocardial T1 mapping: modalities and clinical applications. Cardiovasc Diagn Ther. 2014;4(2):126–37. https://doi.org/10.3978/j.issn.2223-3652.2013.09.03 .
doi: 10.3978/j.issn.2223-3652.2013.09.03
pubmed: 24834410
pmcid: 3996234
Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94(12):3318–26. https://doi.org/10.1161/01.cir.94.12.3318 .
doi: 10.1161/01.cir.94.12.3318
pubmed: 8989146
Berliner JI, Kino A, Carr JC, Bonow RO, Choudhury L. Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging. 2013;29(1):191–7. https://doi.org/10.1007/s10554-012-0048-y .
doi: 10.1007/s10554-012-0048-y
pubmed: 22527259
Shiozaki AA, Senra T, Arteaga E, et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr. 2013;7(3):173–81. https://doi.org/10.1016/j.jcct.2013.04.002 .
doi: 10.1016/j.jcct.2013.04.002
pubmed: 23849490
pmcid: 4128834
Yamada A, Kitagawa K, Nakamura S, et al. Quantification of extracellular volume fraction by cardiac computed tomography for noninvasive assessment of myocardial fibrosis in hemodialysis patients. Sci Rep. 2020;10(1):15367. https://doi.org/10.1038/s41598-020-72417-5 .
doi: 10.1038/s41598-020-72417-5
pubmed: 32958834
pmcid: 7506012
Nacif MS, Kawel N, Lee JJ, et al. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology. 2012;264(3):876–83. https://doi.org/10.1148/radiol.12112458 .
doi: 10.1148/radiol.12112458
pubmed: 22771879
pmcid: 3426854
Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18(1):89. https://doi.org/10.1186/s12968-016-0308-4 .
doi: 10.1186/s12968-016-0308-4
pubmed: 27899132
pmcid: 5129251
Takaoka H, Funabashi N, Uehara M, Iida Y, Kobayashi Y. Diagnostic accuracy of CT for the detection of left ventricular myocardial fibrosis in various myocardial diseases. Int J Cardiol. 2017;228:375–9. https://doi.org/10.1016/j.ijcard.2016.11.140 .
doi: 10.1016/j.ijcard.2016.11.140
pubmed: 27866030
Fritz-Hansen T, Hove JD, Kofoed KF, Kelbaek H, Larsson HB. Quantification of MRI measured myocardial perfusion reserve in healthy humans: a comparison with positron emission tomography. J Magn Reson Imaging. 2008;27(4):818–24. https://doi.org/10.1002/jmri.21306 .
doi: 10.1002/jmri.21306
pubmed: 18383259